Full-Time
LGC Group
1,001-5,000 employees
Provides scientific tools for life sciences
No salary listed
Junior, Mid
Alexandria, MN, USA
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- 1+ years’ experience in Supply Chain Planning or related roles.
- Strong demand planning and supply chain management experience.
- Advanced Excel skills for data analysis and reporting.
- Familiarity with SIOP (Sales, Inventory, & Operations Planning) processes.
- Excellent communication and partner management skills.
- Ability to work independently with minimal supervision.
- Support the Lead Demand Planner in developing site-based forecasts and integrating them within IFS.
- Enhance MRP (Material Requirements Planning) processes to ensure a standardized and efficient planning approach.
- Generate production plans while considering demand, capacity, stock policies, and efficiency factors.
- Identify capacity bottlenecks and collaborate with production teams to develop solutions.
- Monitor key supply chain metrics, conduct root cause analysis, and recommend improvements.
- Facilitate Planning/Production Reviews, ensuring partner alignment and approval.
- Apply IFS exception messages to maintain availability and address shortages.
- Work closely with the logistics team to assess production plans against warehouse capacity.
- 3+ years’ experience in Supply Chain Planning or related roles
- Experience working in a large global organization with multiple manufacturing sites
- IFS ERP system experience in planning, manufacturing, and purchasing modules
LGC Group provides scientific tools and solutions that support advancements in healthcare and pharmaceuticals. Their products include oligo components, probes, primers, and recombinant viral materials, which are essential for detecting diseases and developing vaccines and therapies for various illnesses, including cancer and infectious diseases like COVID-19. LGC serves a wide range of clients, such as healthcare professionals and pharmaceutical companies, and generates revenue through the sale of these specialized tools and proficiency testing schemes that ensure food safety. What sets LGC apart from competitors is its strong focus on quality and innovation, which helps improve healthcare outcomes and contributes to a safer world.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
1841
Simplify's Take
What believers are saying
- Growing demand for nucleic acid-based diagnostics boosts LGC's market potential.
- AI integration in lab processes enhances LGC's efficiency in mass spectrometry and immunoassay.
- Acquisitions like DiaMex and Virusys strengthen LGC's clinical diagnostics portfolio.
What critics are saying
- Increased competition from emerging markets may impact LGC's market share.
- Rapid technological advancements could render LGC's products obsolete without innovation.
- Supply chain vulnerabilities could lead to production delays and increased costs.
What makes LGC Group unique
- LGC Group offers a comprehensive range of high-quality scientific tools and solutions.
- The company has a strong focus on nucleic acid chemistry and recombinant viral materials.
- LGC's proficiency testing schemes enhance food safety and healthcare outcomes globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Remote Work Options
Company News
Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.
For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).
UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.
LGC acquires DiaMex to drive innovation and choice for core laboratory customers: acquisition complements LGC's serology and molecular quality control portfolio and enhances choice of products from a single supplier.
London, UK – 4 December 2024 – LGC today announces an addition to its growing global clinical diagnostics and genomics portfolio, following the acquisition of DiaMex, a manufacturer of third-party serology and molecular quality controls used in clinical laboratories and blood banks across the world.